Carlo L. Bello

Research interests

Publications

• A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

  Clinical Cancer Research · 2009 · https://doi.org/10.1158/1078-0432.ccr-08-1893

• Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

  Clinical Cancer Research · 2009 · https://doi.org/10.1158/1078-0432.ccr-09-0482

• Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

  Cancer Chemotherapy and Pharmacology · 2009 · https://doi.org/10.1007/s00280-009-1170-y

• Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.14.5375

• Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

  Clinical Cancer Research · 2007 · https://doi.org/10.1158/1078-0432.ccr-06-0919

• A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

  Cancer Chemotherapy and Pharmacology · 2007 · https://doi.org/10.1007/s00280-007-0498-4

• Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

  Journal of Translational Medicine · 2007 · https://doi.org/10.1186/1479-5876-5-32

• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

  The Lancet · 2006 · https://doi.org/10.1016/s0140-6736(06)69446-4

• Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

  Anti-Cancer Drugs · 2006 · https://doi.org/10.1097/00001813-200603000-00015

• Sunitinib malate for the treatment of solid tumours: a review of current clinical data

  Expert Opinion on Investigational Drugs · 2006 · https://doi.org/10.1517/13543784.15.5.553

• Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.02.2194

• Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.02.2574

• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

  Blood · 2005 · https://doi.org/10.1182/blood-2004-05-1846

• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  PubMed · 2003

Current projects

No projects listed.